GBP/JPY Price Forecast: Rebounds above 207.00 as oversold risk eases
The GBP/JPY edges higher by about 0.29% on Tuesday, even as risk appetite has shifted to the sour side due to geopolitical developments that are driving global bond yields higher amid inflation fears. At the time of writing, the cross-pair trades at 209.02 after bouncing off daily lows of 208.25.
GBP/JPY Price Forecast: Technical Outlook
Price action in the daily chart shows that the cross is trending lower, following two interventions in the FX markets. This sent GBP/JPY tumbling from around yearly highs near 220.00 to current spot prices, for a loss of over 1,300 pips.
The Relative Strength Index (RSI) remains bearish, though momentum tilted modestly upwards after the index crossed from below 30 to nearly 34. Hence, in the short term, GBP/JPY could aim higher, challenging key resistance levels.
If GBP/JPY crosses the August 3 daily low of 209.58, it opens the door to test 210.00. Even though that is positive for bulls, to change the trend, they must surpass the 200-day Simple Moving Average (SMA) at 213.22, paving the way towards the 215.00 mark.
GBP/JPY Price Chart – Daily
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
China’s gold imports exceeded 1,000 tons by August, surpassing the total for all of 2025.
Crypto prices
More
